News & Insights

TEST FOR TRAINING – This is the headline for this news item.

alt text
July 8, 2024

TEST FOR TRAINING – This is the headline for this news item.

Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.

Subhead here subhead size 4

Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.

 

alt text here

 

Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.

 

LEARN MORE ABOUT THIS ARTICLE >